‘Medusa head ataxia’: the expanding spectrum of Purkinje cell antibodies in autoimmune cerebellar ataxia. Part 3: Anti-Yo/CDR2, anti-Nb/AP3B2, PCA-2, anti-Tr/DNER, other antibodies, diagnostic pitfalls, summary and outlook

Journal of Neuroinflammation

B. Wildemann¹  S. Jarius¹ 

[1] Molecular Neuroimmunology Group, Department of Neurology, University of Heidelberg, Otto Meyerhof Center, Im Neuenheimer Feld 350, Heidelberg, D-69120, Germany

关键词: Voltage-gated calcium channel (VGCC) antibodies;    Neuronal adaptin-like protein (beta-NAP) antibodies;    Anti-AP3B2;    Anti-Nb;    Delta notch-like epidermal growth factor-related receptor (DNER) antibodies;    Anti-Tr;    Purkinje cell antibody 2 (PCA-2);    Cerebellar degeneration-related protein 2-like (CDR2L) antibodies;    Cerebellar degeneration-related protein 2 (CDR2) antibodies;    Anti-Yo;    Glutamate receptor delta2 (GluRδ2) antibodies;    Rho GTPase activating protein 26 (ARHGAP26, GRAF) antibodies;    Anti-Ca;    Protein kinase gamma (PKCγ) antibodies;    Carbonic anhydrase-related protein VIII (CARP VIII) antibodies;    Inositol 1,4,5-trisphosphate receptor 1 (ITPR1, I3PR) antibodies;    Anti-Sj;    Homer-3 antibodies;    Metabotropic glutamate receptor 1 (mGluR1) antibodies;    Purkinje cells;    Autoantibodies;    Paraneoplastic cerebellar degeneration;    Cerebellitis;    Autoimmune cerebellar ataxia;   

Others  :  1227058
DOI  :  10.1186/s12974-015-0358-9

 received in 2015-05-15, accepted in 2015-07-02,  发布年份 2015

【 摘 要 】

Serological testing for anti-neural autoantibodies is important in patients presenting with idiopathic cerebellar ataxia, since these autoantibodies may indicate cancer, determine treatment and predict prognosis. While some of them target nuclear antigens present in all or most CNS neurons (e.g. anti-Hu, anti-Ri), others more specifically target antigens present in the cytoplasm or plasma membrane of Purkinje cells (PC). In this series of articles, we provide a detailed review of the clinical and paraclinical features, oncological, therapeutic and prognostic implications, pathogenetic relevance, and differential laboratory diagnosis of the 12 most common PC autoantibodies (often referred to as ‘Medusa head antibodies’ due to their characteristic somatodendritic binding pattern when tested by immunohistochemistry). To assist immunologists and neurologists in diagnosing these disorders, typical high-resolution immunohistochemical images of all 12 reactivities are presented, diagnostic pitfalls discussed and all currently available assays reviewed. Of note, most of these antibodies target antigens involved in the mGluR1/calcium pathway essential for PC function and survival. Many of the antigens also play a role in spinocerebellar ataxia. Part 1 focuses on anti-metabotropic glutamate receptor 1-, anti-Homer protein homolog 3-, anti-Sj/inositol 1,4,5-trisphosphate receptor- and anti-carbonic anhydrase-related protein VIII-associated autoimmune cerebellar ataxia (ACA); part 2 covers anti-protein kinase C gamma-, anti-glutamate receptor delta-2-, anti-Ca/RhoGTPase-activating protein 26- and anti-voltage-gated calcium channel-associated ACA; and part 3 reviews the current knowledge on anti-Tr/delta notch-like epidermal growth factor-related receptor-, anti-Nb/AP3B2-, anti-Yo/cerebellar degeneration-related protein 2- and Purkinje cell antibody 2-associated ACA, discusses differential diagnostic aspects and provides a summary and outlook.

【 授权许可】

   
2015 Jarius and Wildemann.

【 图 表 】

Fig. 1.

Fig. 2.

Fig. 3.

Fig. 4.

Fig. 5.

Fig. 6.

Fig. 7.

【 参考文献 】

• [1]Jarius S, Wildemann B. ‘Medusa-head ataxia’: the expanding spectrum of Purkinje cell antibodies in autoimmune cerebellar ataxia. Part 1: Anti-mGluR1, anti-Homer-3, anti-Sj/ITPR1 and anti-CARP VIII. J Neuroinflammation. 2015, in press.
• [2]Jarius S, Wildemann B. ‘Medusa head ataxia’: the expanding spectrum of Purkinje cell antibodies in autoimmune cerebellar ataxia. Part 2: Anti-PKC-gamma, anti-GluR-delta2, anti-Ca/ARHGAP26 and anti-VGCC. J Neuroinflammation. 2015, in press.
• [3]Greenlee JE, Brashear HR: Antibodies to cerebellar Purkinje cells in patients with paraneoplastic cerebellar degeneration and ovarian carcinoma. Ann Neurol 1983, 14:609-613.
• [4]Peterson K, Rosenblum MK, Kotanides H, Posner JB: Paraneoplastic cerebellar degeneration. I. A clinical analysis of 55 anti-Yo antibody-positive patients. Neurology 1992, 42:1931-1937.
• [5]Sutton IJ, Fursdon Davis CJ, Esiri MM, Hughes S, Amyes ER, Vincent A: Anti-Yo antibodies and cerebellar degeneration in a man with adenocarcinoma of the esophagus. Ann Neurol 2001, 49:253-257.
• [6]Meglic B, Graus F, Grad A: Anti-Yo-associated paraneoplastic cerebellar degeneration in a man with gastric adenocarcinoma. J Neurol Sci 2001, 185:135-138.
• [7]Krakauer J, Balmaceda C, Gluck JT, Posner JB, Fetell MR, Dalmau J: Anti-Yo-associated paraneoplastic cerebellar degeneration in a man with adenocarcinoma of unknown origin. Neurology 1996, 46:1486-1487.
• [8]Matschke J, Kromminga A, Erbersdobler A, Lamszus K, Anders S, Kofuncu E: Paraneoplastic cerebellar degeneration and anti-Yo antibodies in a man with prostatic adenocarcinoma. J Neurol Neurosurg Psychiatry 2007, 78:775-777.
• [9]Debes JD, Lagarde SM, Hulsenboom E, Sillevis Smitt PA, ten Kate FJ, Sulter GA, van Lanschot JJ, et al.: Anti-Yo-associated paraneoplastic cerebellar degeneration in a man with adenocarcinoma of the gastroesophageal junction. Dig Surg 2007, 24:395-397.
• [10]Stich O, Graus F, Rasiah C, Rauer S: Qualitative evidence of anti-Yo-specific intrathecal antibody synthesis in patients with paraneoplastic cerebellar degeneration. J Neuroimmunol 2003, 141:165-169.
• [11]Titulaer MJ, Soffietti R, Dalmau J, Gilhus NE, Giometto B, Graus F, Grisold W, Honnorat J, Sillevis Smitt PA, Tanasescu R, Vedeler CA, Voltz R, Verschuuren JJ, et al.: Screening for tumours in paraneoplastic syndromes: report of an EFNS task force. Eur J Neurol 2011, 18:19-e13.
• [12]Bhargava A, Bhushan B, Kasundra GM, Shubhakaran K, Pujar GS, Banakar B: Response to abdominal hysterectomy with bilateral salpingo-oophorectomy in postmenopausal woman with anti-Yo antibody mediated paraneoplastic cerebellar degeneration. Ann Indian Acad Neurol 2014, 17:355-357.
• [13]Drlicek M, Bianchi G, Bogliun G, Casati B, Grisold W, Kolig C, Liszka-Setinek U, Marzorati L, Wondrusch E, Cavaletti G, et al.: Antibodies of the anti-Yo and anti-Ri type in the absence of paraneoplastic neurological syndromes: a long-term survey of ovarian cancer patients. J Neurol 1997, 244:85-89.
• [14]Eichler TW, Totland C, Haugen M, Qvale TH, Mazengia K, Storstein A, Haukanes BI, Vedeler CA, et al.: CDR2L antibodies: a new player in paraneoplastic cerebellar degeneration. PLoS One 2013, 8:e66002.
• [15]Rojas I, Graus F, Keime-Guibert F, Rene R, Delattre JY, Ramon JM, Dalmau J, Posner JB, et al.: Long-term clinical outcome of paraneoplastic cerebellar degeneration and anti-Yo antibodies. Neurology 2000, 55:713-715.
• [16]Keime-Guibert F, Graus F, Fleury A, Rene R, Honnorat J, Broet P, Delattre JY, et al.: Treatment of paraneoplastic neurological syndromes with antineuronal antibodies (anti-Hu, anti-Yo) with a combination of immunoglobulins, cyclophosphamide, and methylprednisolone. J Neurol Neurosurg Psychiatry 2000, 68:479-482.
• [17]Phuphanich S, Brock C: Neurologic improvement after high-dose intravenous immunoglobulin therapy in patients with paraneoplastic cerebellar degeneration associated with anti-Purkinje cell antibody. J Neurooncol 2007, 81:67-69.
• [18]Widdess-Walsh P, Tavee JO, Schuele S, Stevens GH: Response to intravenous immunoglobulin in anti-Yo associated paraneoplastic cerebellar degeneration: case report and review of the literature. J Neurooncol 2003, 63:187-190.
• [19]Thone J, Hohaus A, Lamprecht S, Bickel A, Erbguth F: Effective immunosuppressant therapy with cyclophosphamide and corticosteroids in paraneoplastic cerebellar degeneration. J Neurol Sci 2008, 272:171-173.
• [20]Shams’ili S, de Beukelaar J, Gratama JW, Hooijkaas H, van den Bent M, van ‘t Veer M, Sillevis Smitt P, et al.: An uncontrolled trial of rituximab for antibody associated paraneoplastic neurological syndromes. J Neurol 2006, 253:16-20.
• [21]Sakai K, Mitchell DJ, Tsukamoto T, Steinman L: Isolation of a complementary DNA clone encoding an autoantigen recognized by an anti-neuronal cell antibody from a patient with paraneoplastic cerebellar degeneration. Ann Neurol 1990, 28:692-698.
• [22]Fathallah-Shaykh H, Wolf S, Wong E, Posner JB, Furneaux HM: Cloning of a leucine-zipper protein recognized by the sera of patients with antibody-associated paraneoplastic cerebellar degeneration. Proc Natl Acad Sci U S A 1991, 88:3451-3454.
• [23]Darnell JC, Albert ML, Darnell RB: CDR2, a target antigen of naturally occurring human tumor immunity, is widely expressed in gynecological tumors. Cancer Res 2000, 60:2136-2139.
• [24]Corradi JP, Yang C, Darnell JC, Dalmau J, Darnell RB: A post-transcriptional regulatory mechanism restricts expression of the paraneoplastic cerebellar degeneration antigen CDR2 to immune privileged tissues. J Neurosci 1997, 17:1406-1415.
• [25]Furneaux HM, Rosenblum MK, Dalmau J, Wong E, Woodruff P, Graus F, Posner JB, et al.: Selective expression of Purkinje-cell antigens in tumor tissue from patients with paraneoplastic cerebellar degeneration. N Engl J Med 1990, 322:1844-1851.
• [26]Dropcho EJ, Furneaux H, Chen YT, Old LJ, Posner JB: Expression of the CDR brain protein by tumors from patients with paraneoplastic cerebellar degeneration. Ann Neurol 1988, 24:121-122.
• [27]Sakai K, Shirakawa T, Li Y, Kitagawa Y, Hirose G: Interaction of a paraneoplastic cerebellar degeneration-associated neuronal protein with the nuclear helix-loop-helix leucine zipper protein MRG X. Mol Cell Neurosci 2002, 19:477-484.
• [28]Dropcho EJ, Chen YT, Posner JB, Old LJ: Cloning of a brain protein identified by autoantibodies from a patient with paraneoplastic cerebellar degeneration. Proc Natl Acad Sci U S A 1987, 84:4552-4556.
• [29]Furneaux HM, Dropcho EJ, Barbut D, Chen YT, Rosenblum MK, Old LJ, Posner JB, et al.: Characterization of a cDNA encoding a 34-kDa Purkinje neuron protein recognized by sera from patients with paraneoplastic cerebellar degeneration. Proc Natl Acad Sci U S A 1989, 86:2873-2877.
• [30]Totland C, Aarskog NK, Eichler TW, Haugen M, Nostbakken JK, Monstad SE, Salvesen HB, Mork S, Haukanes BI, Vedeler CA, et al.: CDR2 antigen and Yo antibodies. Cancer Immunol Immunother 2011, 60:283-289.
• [31]Darnell RB, Posner JB: Paraneoplastic syndromes. Oxford University Press, Oxford, New York; 2011.
• [32]Schubert M, Panja D, Haugen M, Bramham CR, Vedeler CA: Paraneoplastic CDR2 and CDR2L antibodies affect Purkinje cell calcium homeostasis. Acta Neuropathol 2014, 128:835-852.
• [33]Uhlen M, Fagerberg L, Hallstrom BM, Lindskog C, Oksvold P, Mardinoglu A, Sivertsson A, Kampf C, Sjostedt E, Asplund A, Olsson I, Edlund K, Lundberg E, Navani S, Szigyarto CA, Odeberg J, Djureinovic D, Takanen JO, Hober S, Alm T, Edqvist PH, Berling H, Tegel H, Mulder J, Rockberg J, Nilsson P, Schwenk JM, Hamsten M, von Feilitzen K, Forsberg M, et al.: Proteomics. Tissue-based map of the human proteome. Science 2015, 347:1260419.
• [34]Altermatt HJ, Rodriguez M, Scheithauer BW, Lennon VA: Paraneoplastic anti-Purkinje and type I anti-neuronal nuclear autoantibodies bind selectively to central, peripheral, and autonomic nervous system cells. Lab Invest 1991, 65:412-420.
• [35]Vernino S, Lennon VA: New Purkinje cell antibody (PCA-2): marker of lung cancer-related neurological autoimmunity. Ann Neurol 2000, 47:297-305.
• [36]Graus F, Dalmau J, Valldeoriola F, Ferrer I, Rene R, Marin C, Vecht CJ, Arbizu T, Targa C, Moll JW, et al.: Immunological characterization of a neuronal antibody (anti-Tr) associated with paraneoplastic cerebellar degeneration and Hodgkin’s disease. J Neuroimmunol 1997, 74:55-61.
• [37]Altermatt HJ, Williams CL, Lennon VA: Paraneoplastic cerebellar autoantibodies associated with gynecological cancer bind to myenteric plexus neurons. Ann Neurol 1991, 29:687-688.
• [38]Rodriguez M, Truh LI, O’Neill BP, Lennon VA: Autoimmune paraneoplastic cerebellar degeneration: ultrastructural localization of antibody-binding sites in Purkinje cells. Neurology 1988, 38:1380-1386.
• [39]Tomimoto H, Brengman JM, Yanagihara T: Paraneoplastic cerebellar degeneration with a circulating antibody against neurons and non-neuronal cells. Acta Neuropathol 1993, 86:206-211.
• [40]Hida C, Tsukamoto T, Awano H, Yamamoto T: Ultrastructural localization of anti-Purkinje cell antibody-binding sites in paraneoplastic cerebellar degeneration. Arch Neurol 1994, 51:555-558.
• [41]Storstein A, Monstad SE, Haugen M, Mazengia K, Veltman D, Lohndal E, Aarseth J, Vedeler C, et al.: Onconeural antibodies: improved detection and clinical correlations. J Neuroimmunol 2011, 232:166-170.
• [42]Stich O, Jarius S, Kleer B, Rasiah C, Voltz R, Rauer S: Specific antibody index in cerebrospinal fluid from patients with central and peripheral paraneoplastic neurological syndromes. J Neuroimmunol 2007, 183:220-224.
• [43]Storstein A, Knudsen A, Vedeler CA: Proteasome antibodies in paraneoplastic cerebellar degeneration. J Neuroimmunol 2005, 165:172-178.
• [44]Totland C, Bredholt G, Haugen M, Haukanes BI, Vedeler CA: Antibody to CCDC104 is associated with a paraneoplastic antibody to CDR2 (anti-Yo). Cancer Immunol Immunother 2010, 59:231-237.
• [45]Verschuuren J, Chuang L, Rosenblum MK, Lieberman F, Pryor A, Posner JB, Dalmau J, et al.: Inflammatory infiltrates and complete absence of Purkinje cells in anti-Yo-associated paraneoplastic cerebellar degeneration. Acta Neuropathol 1996, 91:519-525.
• [46]Storstein A, Krossnes BK, Vedeler CA: Morphological and immunohistochemical characterization of paraneoplastic cerebellar degeneration associated with Yo antibodies. Acta Neurol Scand 2009, 120:64-67.
• [47]Giometto B, Marchiori GC, Nicolao P, Scaravilli T, Lion A, Bardin PG, Tavolato B, et al.: Sub-acute cerebellar degeneration with anti-Yo autoantibodies: immunohistochemical analysis of the immune reaction in the central nervous system. Neuropathol Appl Neurobiol 1997, 23:468-474.
• [48]Aboul-Enein F, Hoftberger R, Buxhofer-Ausch V, Drlicek M, Lassmann H, Budka H, Kristoferitsch W, et al.: Neocortical neurones may be targeted by immune attack in anti-Yo paraneoplastic syndrome. Neuropathol Appl Neurobiol 2008, 34:248-252.
• [49]Albert ML, Austin LM, Darnell RB: Detection and treatment of activated T cells in the cerebrospinal fluid of patients with paraneoplastic cerebellar degeneration. Ann Neurol 2000, 47:9-17.
• [50]Bernal F, Shams’ili S, Rojas I, Sanchez-Valle R, Saiz A, Dalmau J, Honnorat J, Sillevis Smitt P, Graus F, et al.: Anti-Tr antibodies as markers of paraneoplastic cerebellar degeneration and Hodgkin’s disease. Neurology 2003, 60:230-234.
• [51]Amyes E, Curnow J, Stark Z, Corlett L, Sutton I, Vincent A: Restricted IgG1 subclass of anti-Yo antibodies in paraneoplastic cerebellar degeneration. J Neuroimmunol 2001, 114:259-264.
• [52]Greenlee JE, Boyden JW, Pingree M, Brashear HR, Clawson SA, Keeney PM: Antibody types and IgG subclasses in paraneoplastic neurological syndromes. J Neurol Sci 2001, 184:131-137.
• [53]Smith JL, Finley JC, Lennon VA: Autoantibodies in paraneoplastic cerebellar degeneration bind to cytoplasmic antigens of Purkinje cells in humans, rats and mice and are of multiple immunoglobulin classes. J Neuroimmunol 1988, 18:37-48.
• [54]Graus F, Illa I, Agusti M, Ribalta T, Cruz-Sanchez F, Juarez C: Effect of intraventricular injection of an anti-Purkinje cell antibody (anti-Yo) in a guinea pig model. J Neurol Sci 1991, 106:82-87.
• [55]Greenlee JE, Burns JB, Rose JW, Jaeckle KA, Clawson S: Uptake of systemically administered human anticerebellar antibody by rat Purkinje cells following blood-brain barrier disruption. Acta Neuropathol 1995, 89:341-345.
• [56]Hill KE, Clawson SA, Rose JW, Carlson NG, Greenlee JE: Cerebellar Purkinje cells incorporate immunoglobulins and immunotoxins in vitro: implications for human neurological disease and immunotherapeutics. J Neuroinflammation 2009, 6:31.
• [57]Greenlee JE, Clawson SA, Hill KE, Wood BL, Tsunoda I, Carlson NG: Purkinje cell death after uptake of anti-Yo antibodies in cerebellar slice cultures. J Neuropathol Exp Neurol 2010, 69:997-1007.
• [58]Tanaka K, Tanaka M, Igarashi S, Onodera O, Miyatake T, Tsuji S: Trial to establish an animal model of paraneoplastic cerebellar degeneration with anti-Yo antibody. 2. Passive transfer of murine mononuclear cells activated with recombinant Yo protein to paraneoplastic cerebellar degeneration lymphocytes in severe combined immunodeficiency mice. Clin Neurol Neurosurg 1995, 97:101-105.
• [59]Borges LF, Busis NA: Intraneuronal accumulation of myeloma proteins. Arch Neurol 1985, 42:690-694.
• [60]Okano HJ, Park WY, Corradi JP, Darnell RB: The cytoplasmic Purkinje onconeural antigen cdr2 down-regulates c-Myc function: implications for neuronal and tumor cell survival. Genes Dev 1999, 13:2087-2097.
• [61]O’Donovan KJ, Diedler J, Couture GC, Fak JJ, Darnell RB: The onconeural antigen cdr2 is a novel APC/C target that acts in mitosis to regulate c-Myc target genes in mammalian tumor cells. PLoS One 2010, 5:e10045.
• [62]Sakai K, Kitagawa Y, Li Y, Shirakawa T, Hirose G: Suppression of the transcriptional activity and DNA binding of nuclear factor-kappa B by a paraneoplastic cerebellar degeneration-associated antigen. J Neuroimmunol 2001, 119:10-15.
• [63]Tanaka K, Tanaka M, Onodera O, Igarashi S, Miyatake T, Tsuji S: Passive transfer and active immunization with the recombinant leucine-zipper (Yo) protein as an attempt to establish an animal model of paraneoplastic cerebellar degeneration. J Neurol Sci 1994, 127:153-158.
• [64]Tanaka M, Tanaka K, Onodera O, Tsuji S: Trial to establish an animal model of paraneoplastic cerebellar degeneration with anti-Yo antibody. 1. Mouse strains bearing different MHC molecules produce antibodies on immunization with recombinant Yo protein, but do not cause Purkinje cell loss. Clin Neurol Neurosurg 1995, 97:95-100.
• [65]Sakai K, Shirakawa T, Kitagawa Y, Li Y, Hirose G: Induction of cytotoxic T lymphocytes specific for paraneoplastic cerebellar degeneration-associated antigen in vivo by DNA immunization. J Autoimmun 2001, 17:297-302.
• [66]Lv D, Shi Q, Liu J, Zhang A, Miao F, He Y, Shen Y, Zhang J, et al.: The similar expression pattern of MHC class I molecules in human and mouse cerebellar cortex. Neurochem Res 2014, 39:180-186.
• [67]Albert ML, Darnell JC, Bender A, Francisco LM, Bhardwaj N, Darnell RB: Tumor-specific killer cells in paraneoplastic cerebellar degeneration. Nat Med 1998, 4:1321-1324.
• [68]Tanaka M, Tanaka K, Tsuji S, Kawata A, Kojima S, Kurokawa T, Kira J, Takiguchi M, et al.: Cytotoxic T cell activity against the peptide, AYRARALEL, from Yo protein of patients with the HLA A24 or B27 supertype and paraneoplastic cerebellar degeneration. J Neurol Sci 2001, 188:61-65.
• [69]Santomasso BD, Roberts WK, Thomas A, Williams T, Blachere NE, Dudley ME, Houghton AN, Posner JB, Darnell RB, et al.: A T-cell receptor associated with naturally occurring human tumor immunity. Proc Natl Acad Sci U S A 2007, 104:19073-19078.
• [70]Sutton IJ, Steele J, Savage CO, Winer JB, Young LS: An interferon-gamma ELISPOT and immunohistochemical investigation of cytotoxic T lymphocyte-mediated tumour immunity in patients with paraneoplastic cerebellar degeneration and anti-Yo antibodies. J Neuroimmunol 2004, 150:98-106.
• [71]Tani T, Tanaka K, Idezuka J, Nishizawa M: Regulatory T cells in paraneoplastic neurological syndromes. J Neuroimmunol 2008, 196:166-169.
• [72]Carpenter EL, Vance BA, Klein RS, Voloschin A, Dalmau J, Vonderheide RH: Functional analysis of CD8+ T cell responses to the onconeural self protein CDR2 in patients with paraneoplastic cerebellar degeneration. J Neuroimmunol 2008, 193:173-182.
• [73]Darnell RB, Furneaux HM, Posner JB: Characterization of antigens bound by CSF and serum of a patient with cerebellar degeneration: co-expression in Purkinje cells and tumor lines of neuroectodermal origin. Neurology 1989, 39(Suppl):260.
• [74]Darnell RB, Furneaux HM, Posner JB: Antiserum from a patient with cerebellar degeneration identifies a novel protein in Purkinje cells, cortical neurons, and neuroectodermal tumors. J Neurosci 1991, 11:1224-1230.
• [75]Newman LS, Mckeever MO, Okano HJ, Darnell RB: Beta-NAP, a cerebellar degeneration antigen, is a neuron-specific vesicle coat protein. Cell 1995, 82:773-783.
• [76]Blumstein J, Faundez V, Nakatsu F, Saito T, Ohno H, Kelly RB: The neuronal form of adaptor protein-3 is required for synaptic vesicle formation from endosomes. J Neurosci 2001, 21:8034-8042.
• [77]Nakatsu F, Okada M, Mori F, Kumazawa N, Iwasa H, Zhu G, Kasagi Y, Kamiya H, Harada A, Nishimura K, Takeuchi A, Miyazaki T, Watanabe M, Yuasa S, Manabe T, Wakabayashi K, Kaneko S, Saito T, Ohno H, et al.: Defective function of GABA-containing synaptic vesicles in mice lacking the AP-3B clathrin adaptor. J Cell Biol 2004, 167:293-302.
• [78]Seong E, Wainer BH, Hughes ED, Saunders TL, Burmeister M, Faundez V: Genetic analysis of the neuronal and ubiquitous AP-3 adaptor complexes reveals divergent functions in brain. Mol Biol Cell 2005, 16:128-140.
• [79]Grabner CP, Price SD, Lysakowski A, Cahill AL, Fox AP: Regulation of large dense-core vesicle volume and neurotransmitter content mediated by adaptor protein 3. Proc Natl Acad Sci U S A 2006, 103:10035-10040.
• [80]Jarius S, Eichhorn P, Wildemann B, Wick M: Usefulness of antibody index assessment in cerebrospinal fluid from patients negative for total-IgG oligoclonal bands. Fluids Barriers CNS 2012, 9:14.
• [81]Jarius S, Stich O, Speck J, Rasiah C, Wildemann B, Meinck HM, Rauer S, et al.: Qualitative and quantitative evidence of anti-glutamic acid decarboxylase-specific intrathecal antibody synthesis in patients with stiff person syndrome. J Neuroimmunol 2010, 229:219-224.
• [82]Jarius S, Stich O, Rasiah C, Voltz R, Rauer S: Qualitative evidence of Ri specific IgG-synthesis in the cerebrospinal fluid from patients with paraneoplastic neurological syndromes. J Neurol Sci 2008, 268:65-68.
• [83]Stich O, Kluge J, Speck J, Rauer S. Oligoclonal restriction of antiviral immunoreaction in oligoclonal band-negative MS patients. Acta Neurol Scand. 2015;131:381–8.
• [84]Stich O, Rauer S: Antigen-specific oligoclonal bands in cerebrospinal fluid and serum from patients with anti-amphiphysin- and anti-CV2/CRMP5 associated paraneoplastic neurological syndromes. Eur J Neurol 2007, 14:650-653.
• [85]Lim DS, Kirsch DG, Canman CE, Ahn JH, Ziv Y, Newman LS, Darnell RB, Shiloh Y, Kastan MB, et al.: ATM binds to beta-adaptin in cytoplasmic vesicles. Proc Natl Acad Sci U S A 1998, 95:10146-10151.
• [86]Fletcher CF, Okano HJ, Gilbert DJ, Yang Y, Yang C, Copeland NG, Jenkins NA, Darnell RB, et al.: Mouse chromosomal locations of nine genes encoding homologs of human paraneoplastic neurologic disorder antigens. Genomics 1997, 45:313-319.
• [87]de Graaff E, Maat P, Hulsenboom E, van den Berg R, van den Bent M, Demmers J, Lugtenburg PJ, Hoogenraad CC, Sillevis Smitt P, et al.: Identification of delta/notch-like epidermal growth factor-related receptor as the Tr antigen in paraneoplastic cerebellar degeneration. Ann Neurol 2012, 71:815-824.
• [88]Trotter JL, Hendin BA, Osterland CK: Cerebellar degeneration with Hodgkin disease. An immunological study. Arch Neurol 1976, 33:660-661.
• [89]Probst C, Komorowski L, de Graaff E, van Coevorden-Hameete M, Rogemond V, Honnorat J, Sabeter L, Graus F, Jarius S, Voltz R, Wildemann B, Franciotta D, Blocker IM, Schlumberger W, Stocker W, Sillevis Smitt PA, et al.: Standardized test for anti-Tr/DNER in patients with paraneoplastic cerebellar degeneration. Neurol Neuroimmunol Neuroinflamm 2015, 2:e68.
• [90]Bruylant K, Crols R, Humbel RL, Appel B, De Deyn PP: Probably anti-Tr associated paraneoplastic cerebellar degeneration as initial presentation of a squamous cell carcinoma of the lung. Clin Neurol Neurosurg 2006, 108:415-417.
• [91]Eiraku M, Hirata Y, Takeshima H, Hirano T, Kengaku M: Delta/notch-like epidermal growth factor (EGF)-related receptor, a novel EGF-like repeat-containing protein targeted to dendrites of developing and adult central nervous system neurons. J Biol Chem 2002, 277:25400-25407.
• [92]Eiraku M, Tohgo A, Ono K, Kaneko M, Fujishima K, Hirano T, Kengaku M, et al.: DNER acts as a neuron-specific notch ligand during Bergmann glial development. Nat Neurosci 2005, 8:873-880.
• [93]Tohgo A, Eiraku M, Miyazaki T, Miura E, Kawaguchi SY, Nishi M, Watanabe M, Hirano T, Kengaku M, Takeshima H, et al.: Impaired cerebellar functions in mutant mice lacking DNER. Mol Cell Neurosci 2006, 31:326-333.
• [94]Graus F, Gultekin SH, Ferrer I, Reiriz J, Alberch J, Dalmau J: Localization of the neuronal antigen recognized by anti-Tr antibodies from patients with paraneoplastic cerebellar degeneration and Hodgkin’s disease in the rat nervous system. Acta Neuropathol 1998, 96:1-7.
• [95]Nishizumi H, Komiyama T, Miyabayashi T, Sakano S, Sakano H: BET, a novel neuronal transmembrane protein with multiple EGF-like motifs. Neuroreport 2002, 13:909-915.
• [96]Greene M, Lai Y, Baella N, Dalmau J, Lancaster E: Antibodies to Delta/notch-like epidermal growth factor-related receptor in patients with anti-Tr, paraneoplastic cerebellar degeneration, and Hodgkin lymphoma. JAMA Neurol 2014, 71:1003-1008.
• [97]Hammack JE, Kimmel DW, O’Neill BP, Lennon VA: Paraneoplastic cerebellar degeneration: a clinical comparison of patients with and without Purkinje cell cytoplasmic antibodies. Mayo Clin Proc 1990, 65:1423-1431.
• [98]Jarius S, Wildemann B, Paul F: Neuromyelitis optica: clinical features, immunopathogenesis and treatment. Clin Exp Immunol 2014, 176:149-164.
• [99]Jarius S, Wildemann B: AQP4 antibodies in neuromyelitis optica: diagnostic and pathogenetic relevance. Nat Rev Neurol 2010, 6:383-392.
• [100]Jarius S, Paul F, Franciotta D, Waters P, Zipp F, Hohlfeld R, Vincent A, Wildemann B, et al.: Mechanisms of disease: aquaporin-4 antibodies in neuromyelitis optica. Nat Clin Pract Neurol 2008, 4:202-214.
• [101]Desforges JF, Rutherford CJ, Piro A: Hodgkin’s disease. N Engl J Med 1979, 301:1212-1222.
• [102]Longmire RL, McMillan R, Yelenosky R, Armstrong S, Lang JE, Craddock CG: In vitro splenic IgG synthesis in Hodgkin’s disease. N Engl J Med 1973, 289:763-767.
• [103]Greenlee JE, Dalmau J, Lyons T, Clawson S, Smith RH, Pirch HR: Association of anti-Yo (type I) antibody with paraneoplastic cerebellar degeneration in the setting of transitional cell carcinoma of the bladder: detection of Yo antigen in tumor tissue and fall in antibody titers following tumor removal. Ann Neurol 1999, 45:805-809.
• [104]Stark E, Wurster U, Patzold U, Sailer M, Haas J: Immunological and clinical response to immunosuppressive treatment in paraneoplastic cerebellar degeneration. Arch Neurol 1995, 52:814-818.
• [105]Rauer S, Czygan M, Kaiser R: Quantification of circulating anti-Hu antibody in serial samples from patients with paraneoplastic neurological syndromes: possible correlation of antibody concentration and course of neurological symptoms. J Neurol 2002, 249:285-289.
• [106]Balint B, Jarius S, Nagel S, Haberkorn U, Probst C, Blocker IM, Bahtz R, Komorowski L, Stocker W, Kastrup A, Kuthe M, Meinck HM, et al.: Progressive encephalomyelitis with rigidity and myoclonus: a new variant with DPPX antibodies. Neurology 2014, 82:1521-1528.
• [107]Boronat A, Gelfand JM, Gresa-Arribas N, Jeong H-Y, Walsh M, Roberts K, et al. Encephalitis and antibodies to DPPX, a subunit of Kv4.2 potassium channels. AnnNeurol. 2012. In press (DOI: 10.1002/ana.23756).
• [108]Stoeck K, Carstens P, Jarius S, Raddatz D, Stöcker W, Wildemann B, Schmidt J, et al.: Prednisolone and azathioprine are effective in DPPX antibody–positive autoimmune encephalitis. Neurol Neuroimmunol Neuroinflamm 2015, 2:e86.
• [109]Becker EB, Zuliani L, Pettingill R, Lang B, Waters P, Dulneva A, Sobott F, Wardle M, Graus F, Bataller L, Robertson NP, Vincent A, et al.: Contactin-associated protein-2 antibodies in non-paraneoplastic cerebellar ataxia. J Neurol Neurosurg Psychiatry 2012, 83:437-440.
• [110]Balint B, Regula JU, Jarius S, Wildemann B: Caspr2 antibodies in limbic encephalitis with cerebellar ataxia, dyskinesias and myoclonus. J Neurol Sci 2013, 327:73-74.
• [111]Steriade C, Day GS, Lee L, Murray BJ, Fritzler MJ, Keith J: LGI1 autoantibodies associated with cerebellar degeneration. Neuropathol Appl Neurobiol 2014, 40:645-649.
• [112]Jarius S, Wildemann B: Aquaporin-4 antibodies (NMO-IgG) as a serological marker of neuromyelitis optica: a critical review of the literature. Brain Pathol 2013, 23:661-683.
• [113]Jarius S, Ruprecht K, Wildemann B, Kuempfel T, Ringelstein M, Geis C, Kleiter I, Kleinschnitz C, Berthele A, Brettschneider J, Hellwig K, Hemmer B, Linker RA, Lauda F, Mayer CA, Tumani H, Melms A, Trebst C, Stangel M, Marziniak M, Hoffmann F, Schippling S, Faiss JH, Neuhaus O, Ettrich B, Zentner C, Guthke K, Hofstadt-van Oy U, Reuss R, Pellkofer H, et al.: Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients. J Neuroinflammation 2012, 9:14.
• [114]Hadjivassiliou M, Aeschlimann P, Strigun A, Sanders DS, Woodroofe N, Aeschlimann D: Autoantibodies in gluten ataxia recognize a novel neuronal transglutaminase. Ann Neurol 2008, 64:332-343.
• [115]McKeon A, Lennon VA, Pittock SJ, Kryzer TJ, Murray J: The neurologic significance of celiac disease biomarkers. Neurology 2014, 83:1789-1796.
• [116]Fritzler MJ, Zhang M, Stinton LM, Rattner JB: Spectrum of centrosome autoantibodies in childhood varicella and post-varicella acute cerebellar ataxia. BMC Pediatr 2003, 3:11.
• [117]Cimolai N, Mah D, Roland E: Anticentriolar autoantibodies in children with central nervous system manifestations of Mycoplasma pneumoniae infection. J Neurol Neurosurg Psychiatry 1994, 57:638-639.
• [118]Uchibori A, Sakuta M, Kusunoki S, Chiba A: Autoantibodies in postinfectious acute cerebellar ataxia. Neurology 2005, 65:1114-1116.
• [119]Ichikawa H, Susuki K, Yuki N, Kawamura M: Ataxic form of Guillain-Barré syndrome associated with anti-GD1b IgG antibody. Rinsho Shinkeigaku 2001, 41:523-525.
• [120]Araki T, Nakata H, Kusunoki S, Arai Y, Katayama Y: Immunoadsorption therapy with TR-350 (tryptophan column) for Guillain-Barré syndrome: investigation including serum antiganglioside antibody assay. Rinsho Shinkeigaku 2000, 40:979-985.
• [121]Kaida K, Kamakura K, Ogawa G, Ueda M, Motoyoshi K, Arita M, Kusunoki S, et al.: GD1b-specific antibody induces ataxia in Guillain-Barré syndrome. Neurology 2008, 71:196-201.
• [122]Ito M, Matsuno K, Sakumoto Y, Hirata K, Yuki N: Ataxic Guillain-Barré syndrome and acute sensory ataxic neuropathy form a continuous spectrum. J Neurol Neurosurg Psychiatry 2011, 82:294-299.
• [123]Lennon VA: The case for a descriptive generic nomenclature: clarification of immunostaining criteria for PCA-1, ANNA-1, and ANNA-2 autoantibodies. Neurology 1994, 44:2412-2415.
• [124]Jarius S, Franciotta D, Bergamaschi R, Wright H, Littleton E, Palace J, Hohlfeld R, Vincent A, et al.: NMO-IgG in the diagnosis of neuromyelitis optica. Neurology 2007, 68:1076-1077.
• [125]Greenlee JE, Brashear HR, Herndon RM: Immunoperoxidase labelling of rat brain sections with sera from patients with paraneoplastic cerebellar degeneration and systemic neoplasia. J Neuropathol Exp Neurol 1988, 47:561-571.
• [126]Jaeckle KA, Graus F, Houghton A, Cardon-Cardo C, Nielsen SL, Posner JB: Autoimmune response of patients with paraneoplastic cerebellar degeneration to a Purkinje cell cytoplasmic protein antigen. Ann Neurol 1985, 18:592-600.
• [127]Bataller L, Sabater L, Saiz A, Serra C, Claramonte B, Graus F: Carbonic anhydrase-related protein VIII: autoantigen in paraneoplastic cerebellar degeneration. Ann Neurol 2004, 56:575-579.
• [128]Jarius S, Probst C, Borowski K, Franciotta D, Wildemann B, Stoecker W, Wandinger KP, et al.: Standardized method for the detection of antibodies to aquaporin-4 based on a highly sensitive immunofluorescence assay employing recombinant target antigen. J Neurol Sci 2010, 291:52-56.
• [129]Jarius S, Scharf M, Begemann N, Stocker W, Probst C, Serysheva II, Nagel S, Graus F, Psimaras D, Wildemann B, Komorowski L, et al.: Antibodies to the inositol 1,4,5-trisphosphate receptor type 1 (ITPR1) in cerebellar ataxia. J Neuroinflammation 2014, 11:206.
• [130]Jarius S, Wandinger KP, Horn S, Heuer H, Wildemann B: A new Purkinje cell antibody (anti-Ca) associated with subacute cerebellar ataxia: immunological characterization. J Neuroinflammation 2010, 7:21.
• [131]Dubois-Galopin F, Beauvillain C, Dubois D, Pillet A, Renier G, Jeannin P, Masson C, Chevailler A, et al.: New markers and an old phenomenon: prozone effect disturbing detection of filaggrin (keratin) autoantibodies. Ann Rheum Dis 2007, 66:1121-1122.
• [132]Mundiyanapurath S, Jarius S, Probst C, Stocker W, Wildemann B, Bosel J: GABA-B-receptor antibodies in paraneoplastic brainstem encephalitis. J Neuroimmunol 2013, 259:88-91.
• [133]McKeon A, Martinez-Hernandez E, Lancaster E, Matsumoto JY, Harvey RJ, McEvoy KM, Pittock SJ, Lennon VA, Dalmau J, et al.: Glycine receptor autoimmune spectrum with stiff-man syndrome phenotype. JAMA Neurol 2013, 70:44-50.
• [134]Pittock SJ, Parisi JE, McKeon A, Roemer SF, Lucchinetti CF, Tan KM, Keegan BM, Hunter SF, Duncan PR, Baehring JM, Matsumoto JY, Lennon VA, et al.: Paraneoplastic jaw dystonia and laryngospasm with antineuronal nuclear autoantibody type 2 (anti-Ri). Arch Neurol 2010, 67:1109-1115.
• [135]Reindl M, Di Pauli F, Rostasy K, Berger T: The spectrum of MOG autoantibody-associated demyelinating diseases. Nat Rev Neurol 2013, 9:455-461.
• [136]Fabian RH, Petroff G: Intraneuronal IgG in the central nervous system: uptake by retrograde axonal transport. Neurology 1987, 37:1780-1784.
• [137]Fabian RH, Ritchie TC: Intraneuronal IgG in the central nervous system. J Neurol Sci 1986, 73:257-267.
• [138]Martin-Garcia E, Mannara F, Gutierrez-Cuesta J, Sabater L, Dalmau J, Maldonado R, Graus F, et al.: Intrathecal injection of P/Q type voltage-gated calcium channel antibodies from paraneoplastic cerebellar degeneration cause ataxia in mice. J Neuroimmunol 2013, 261:53-59.
• [139]Sakai K, Gofuku M, Kitagawa Y, Ogasawara T, Hirose G: Induction of anti-Purkinje cell antibodies in vivo by immunizing with a recombinant 52-kDa paraneoplastic cerebellar degeneration-associated protein. J Neuroimmunol 1995, 60:135-141.
• [140]Orrenius S, Zhivotovsky B, Nicotera P: Regulation of cell death: the calcium-apoptosis link. Nat Rev Mol Cell Biol 2003, 4:552-565.
• [141]Sommer C, Weishaupt A, Brinkhoff J, Biko L, Wessig C, Gold R, Toyka KV, et al.: Paraneoplastic stiff-person syndrome: passive transfer to rats by means of IgG antibodies to amphiphysin. Lancet 2005, 365:1406-1411.
• [142]Geis C, Weishaupt A, Hallermann S, Grunewald B, Wessig C, Wultsch T, Reif A, Byts N, Beck M, Jablonka S, Boettger MK, Uceyler N, Fouquet W, Gerlach M, Meinck HM, Siren AL, Sigrist SJ, Toyka KV, Heckmann M, Sommer C, et al.: Stiff person syndrome-associated autoantibodies to amphiphysin mediate reduced GABAergic inhibition. Brain 2010, 133:3166-3180.
• [143]Vincent A: Successful ‘passive transfer’ of paraneoplastic stiff person syndrome with antibodies to an intracellular antigen. Brain 2010, 133:3164-3165.
• [144]Geis C, Grunewald B, Weishaupt A, Wultsch T, Toyka KV, Reif A, Sommer C, et al.: Human IgG directed against amphiphysin induces anxiety behavior in a rat model after intrathecal passive transfer. J Neural Transm 2012, 119:981-985.
• [145]Lundmark R, Doherty GJ, Howes MT, Cortese K, Vallis Y, Parton RG, McMahon HT, et al.: The GTPase-activating protein GRAF1 regulates the CLIC/GEEC endocytic pathway. Curr Biol 2008, 18:1802-1808.
• [146]Shiraga S, Adamus G: Mechanism of CAR syndrome: anti-recoverin antibodies are the inducers of retinal cell apoptotic death via the caspase 9- and caspase 3-dependent pathway. J Neuroimmunol 2002, 132:72-82.
• [147]Hansen N, Grunewald B, Weishaupt A, Colaco MN, Toyka KV, Sommer C, Geis C, et al.: Human stiff person syndrome IgG-containing high-titer anti-GAD65 autoantibodies induce motor dysfunction in rats. Exp Neurol 2013, 239:202-209.
• [148]Geis C, Weishaupt A, Grunewald B, Wultsch T, Reif A, Gerlach M, Dirkx R, Solimena M, Perani D, Heckmann M, Toyka KV, Folli F, Sommer C, et al.: Human stiff-person syndrome IgG induces anxious behavior in rats. PLoS One 2011, 6:e16775.
• [149]Golan TD, Gharavi AE, Elkon KB: Penetration of autoantibodies into living epithelial cells. J Invest Dermatol 1993, 100:316-322.
• [150]Zack DJ, Stempniak M, Wong AL, Taylor C, Weisbart RH: Mechanisms of cellular penetration and nuclear localization of an anti-double strand DNA autoantibody. J Immunol 1996, 157:2082-2088.
• [151]Yanase K, Smith RM, Puccetti A, Jarett L, Madaio MP: Receptor-mediated cellular entry of nuclear localizing anti-DNA antibodies via myosin 1. J Clin Invest 1997, 100:25-31.
• [152]Anderson NE, Budde-Steffen C, Wiley RG, Thurman L, Rosenblum MK, Nadeau SE, Posner JB, et al.: A variant of the anti-Purkinje cell antibody in a patient with paraneoplastic cerebellar degeneration. Neurology 1988, 38:1018-1026.